Dr. Drilon on NTRK Rearrangement in Lung Cancer

Alexander Drilon, MD
Published: Thursday, Mar 02, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

NTRK rearrangements are recurrent gene fusions that are found in a rare minority of patients with lung cancer, explains Drilon. However, looking across other solid tumors, they can be found in head and neck cancer, sarcomas, and breast cancer.

According to Drilon, the interesting thing about TRK fusions, is that they are very actionable in terms of targeted therapy. There are 2 different targeted agents, entrectinib and LOXO-101, that are in phase II testing for any patients who have solid tumors with NTRK rearrangement. Both drugs have achieved dramatic responses, regardless of histology in earlier phase I studies.
 
SELECTED
LANGUAGE


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.

NTRK rearrangements are recurrent gene fusions that are found in a rare minority of patients with lung cancer, explains Drilon. However, looking across other solid tumors, they can be found in head and neck cancer, sarcomas, and breast cancer.

According to Drilon, the interesting thing about TRK fusions, is that they are very actionable in terms of targeted therapy. There are 2 different targeted agents, entrectinib and LOXO-101, that are in phase II testing for any patients who have solid tumors with NTRK rearrangement. Both drugs have achieved dramatic responses, regardless of histology in earlier phase I studies.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x